BOULDER, Colo., Nov. 1 /PRNewswire/ -- SomaLogic, Inc., a privately-held proteomics company, announced today that it has received Frost & Sullivan's 2004 Technology Innovation Award in the field of biomarkers. In its recent study, Biomarkers: Promising Research, Potential Applications and New Developments, Frost & Sullivan recognized the potential of SomaLogic's proprietary photoaptamer arrays to set the standard for the simultaneous analysis of large numbers of proteins in clinical samples.
"We are honored by this award, particularly since Frost & Sullivan reviewed the full range of technologies for biomarker discovery and development," commented Dr. Larry Gold, Chairman and Chief Science Officer of SomaLogic. "As a proteomics-based diagnostics company, the discovery of new biomarkers and patterns of biomarkers -- protein signatures -- is at the very heart of what we do."
SomaLogic's arrays use photoaptamers to capture and bind target proteins, avoiding many of the challenges associated with antibody-based arrays. Photoaptamers are single-stranded nucleic acids (most often DNA) that assume three-dimensional shapes and bind their target molecules with high affinity and specificity. Because they can also form specific covalent bonds with their target proteins, photoaptamers are ideal for array applications. Background proteins can be washed away under harsh conditions (reducing noise) and the amount of protein present can be assessed using a simple universal protein stain. Neither of these approaches can be used with antibodies. Moreover, by eliminating the cross-talk associated with secondary antibodies, photoaptamer arrays substantially increase the number of simultaneous measurements on each clinical sample.
"Somalogic's technology promises to deliver a scale that approaches that of 2-D gel electrophoresis but with performance comparable to ELISAs," said Frost & Sullivan Research Analyst S. Ravi Shankar. "The Frost & Sullivan Award for Technology Innovation recognizes Somalogic for its outstanding efforts in developing protein array technology that could help overcome the industry's twin challenges of robustness and scalability."
"This is the real strength of photoaptamer arrays," observed Dr. Gold. "In the search for biomarkers and protein signatures, it is important not only to have high-quality assays but to assess simultaneously as many potential biomarkers as possible."
In addition to diagnostics that target significant unmet needs in clinical medicine, SomaLogic is developing strategic alliances to make its technology available to researchers in the academic, biotechnology, and pharmaceutical fields.
About Frost & Sullivan's Technology Innovation Award
With a client list that includes Global 1000 companies, emerging companies, as well as the investment community, Frost & Sullivan has evolved into one of the premier growth consulting companies in the world. Frost & Sullivan's Technology Innovation Award for biomarkers is given to a company (or individual) that has carried out new research that has resulted in innovation(s) that either have or are expected to provide significant contributions to the biomarker field in terms of adoption, change, and competitive posture. It recognizes the quality and depth of a research and development program as well as the vision and risk-taking that enabled the recipient to undertake such an endeavor.
About SomaLogic, Inc.
SomaLogic is developing novel proteomics systems and applications based on its proprietary photoaptamer technology. The company is developing clinical diagnostics that will address unmet needs in the areas of disease screening, diagnosis, therapeutic management, and monitoring. SomaLogic is headquartered in Boulder, Colorado. Further information about the company can be found at http://www.somalogic.com/.